Overview

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Status:
Recruiting
Trial end date:
2025-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Biohaven Pharmaceuticals, Inc.
Treatments:
Ipilimumab
Nivolumab